Mitchell Hayes

Mitchell Hayes

Auto-generated profile, based on publicly available information

Mitchell Hayes

McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, United States of America

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2013 in Oncogene
Verified
Journal Article
Closed access
PDF file
DVD T Vereide
D T Vereide
ESE Seto
E Seto
YCY-F Chiu
Y-F Chiu
MHM Hayes
M Hayes
TTTakanobu Tagawa
Takanobu Tagawa
BSBill Sugden
Bill Sugden

12 September 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TTTakanobu Tagawa
Takanobu Tagawa
MAManuel Albanese
Manuel Albanese
MBMickaël Bouvet
Mickaël Bouvet
AMAndreas Moosmann
Andreas Moosmann
JMJosef Mautner
Josef Mautner
WHWolfgang Hammerschmidt
Wolfgang Hammerschmidt
Epstein-Barr virus (EBV) is a tumor virus that establishes lifelong infection in most of humanity, despite eliciting strong and stable virus-specific immune responses. EBV encodes at least 44 miRNAs, most of them with unknown function. Here, we show that multiple EBV miRNAs modulate immune recognition of recently infected primary B cells, EBV's natural target cells. EBV miRNAs collectively and specifically suppress release of proinflammatory cytokines such as IL-12, repress differentiation of naive CD4+ T cells to Th1 cells, interfere with peptide processing and presentation on HLA class II, and thus reduce activation of cytotoxic EBV-specific CD4+ effector T cells and killing of infected B cells. Our findings identify a previously unknown viral strategy of immune evasion. By rapidly expressing multiple miRNAs, which are themselves nonimmunogenic, EBV counteracts recognition by CD4+ T cells and establishes a program of reduced immunogenicity in recently infected B cells, allowing the virus to express viral proteins required for establishment of life-long infection.

27 July 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
JBJillian A Bristol
Jillian A Bristol
RDReza Djavadian
Reza Djavadian
EAEmily R Albright
Emily R Albright
CCCarrie B Coleman
Carrie B Coleman
MOMakoto Ohashi
Makoto Ohashi
SKShannon C. Kenney
Shannon C. Kenney
Latent Epstein-Barr virus (EBV) infection contributes to both B-cell and epithelial-cell malignancies. However, whether lytic EBV infection also contributes to tumors is unclear, although the association between malaria infection and Burkitt lymphomas (BLs) may involve excessive lytic EBV replication. A particular variant of the viral promoter (Zp) that controls lytic EBV reactivation is over-represented, relative to its frequency in non-malignant tissue, in EBV-positive nasopharyngeal carcinomas and AIDS-related lymphomas. To date, no functional differences between the prototype Zp (Zp-P) and the cancer-associated variant (Zp-V3) have been identified. Here we show that a single nucleotide difference between the Zp-V3 and Zp-P promoters creates a binding site for the cellular transcription factor, NFATc1, in the Zp-V3 (but not Zp-P) variant, and greatly enhances Zp activity and lytic viral reactivation in response to NFATc1-inducing stimuli such as B-cell receptor activation and ionomycin. Furthermore, we demonstrate that restoring this NFATc1-motif to the Zp-P variant in the context of the intact EBV B95.8 strain genome greatly enhances lytic viral reactivation in response to the NFATc1-activating agent, ionomycin, and this effect is blocked by the NFAT inhibitory agent, cyclosporine, as well as NFATc1 siRNA. We also show that the Zp-V3 variant is over-represented in EBV-positive BLs and gastric cancers, and in EBV-transformed B-cell lines derived from EBV-infected breast milk of Kenyan mothers that had malaria during pregnancy. These results demonstrate that the Zp-V3 enhances EBV lytic reactivation to physiologically-relevant stimuli, and suggest that increased lytic infection may contribute to the increased prevalence of this variant in EBV-associated malignancies. Whether excessive lytic EBV infection increases the risk of EBV-induced cancers is not clear. A particular variant (Zp-V3) of the viral promoter driving expression of the EBV immediate-early BZLF1 (Z) protein that mediates lytic viral reactivation has been reported to be over-represented (relative to the prototype Zp-P form of the promoter) in certain EBV-positive malignancies, but no functional difference between the two promoter variants has been reported. Here we show that the malignancy-associated Zp-V3 variant (but not the Zp-P variant) contains a binding site for the cellular NFATc1 (nuclear factor of activated T cells c1) transcription factor that allows it to be activated by NFATc1-inducing stimuli such as B-cell receptor stimulation. Furthermore, we demonstrate that restoring this NFATc1-motif to the Zp-P variant in the context of the intact EBV genome greatly enhances lytic viral reactivation in response to the NFATc1-inducing stimuli. We also find that the Zp-V3 variant is over-represented in EBV-positive Burkitt lymphomas and gastric carcinomas, and in lymphoblastoid cell lines transformed by EBV-infected breast milk of Kenyan mothers that had malaria during pregnancy. These findings suggest that the Zp-V3 version of the EBV BZLF1 promoter increases the likelihood of EBV-induced malignancies by increasing lytic EBV infection.

4 June 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
RDReza Djavadian
Reza Djavadian
MHMitchell Hayes
Mitchell Hayes
EJEric C Johannsen
Eric C Johannsen
Epstein-Barr virus (EBV) lytic replication proceeds through an ordered cascade of gene expression that integrates lytic DNA amplification and late gene transcription. We and others previously demonstrated that 6 EBV proteins that have orthologs in β- and γ-, but not in α-herpesviruses, mediate late gene transcription in a lytic DNA replication-dependent manner. We proposed a model in which the βγ gene-encoded viral pre-initiation complex (vPIC) mediates transcription from newly replicated viral DNA. While this model explains the dependence of late gene transcription on lytic DNA replication, it does not account for this dependence in α-herpesviruses nor for recent reports that some EBV late genes are transcribed independently of vPIC. To rigorously define which transcription start sites (TSS) are dependent on viral lytic DNA replication or the βγ complex, we performed Cap Analysis of Gene Expression (CAGE)-seq on cells infected with wildtype EBV or EBV mutants defective for DNA replication, βγ function, or lacking an origin of lytic replication (OriLyt). This approach identified 16 true-late, 32 early, and 16 TSS that are active at low levels early and are further upregulated in a DNA replication-dependent manner (leaky late). Almost all late gene transcription is vPIC-dependent, with BCRF1 (vIL10), BDLF2, and BDLF3 transcripts being notable exceptions. We present evidence that leaky late transcription is not due to a distinct mechanism, but results from superimposition of the early and late transcription mechanisms at the same promoter. Our results represent the most comprehensive characterization of EBV lytic gene expression kinetics reported to date and suggest that most, but not all EBV late genes are vPIC-dependent. Herpesvirus lytic replication is characterized by the expression of early genes prior to viral DNA replication followed by late gene expression. Late genes are not only expressed after DNA replication, but cannot be expressed in its absence. We and others have shown that γ-herpesviruses, such as Epstein-Barr virus (EBV), as well as β-herpesviruses accomplish late gene transcription using a viral pre-initiation complex (vPIC). Proteins in this complex are encoded by genes with orthologs found only in β- and γ-herpesviruses (βγ genes) and absent in α-herpesviruses. We used EBV mutants defective for DNA replication or βγ complex/vPIC function to rigorously identify all EBV late genes and determine the extent of their dependence upon vPIC for expression. Because of the extensive bidirectional transcription of the EBV genome during lytic replication, unambiguous quantification of most lytic transcripts is not possible by conventional methods such as RNA-seq and RT-qPCR. We therefore used deep sequencing of non-amplified 5’ ends to uniquely localize and quantify transcription start sites in a strand-specific manner. Our results demonstrate that most, but not all, EBV late transcripts require vPIC for their expression. Furthermore, our results indicate that transcription that appears to be partially dependent on DNA replication (called “leaky” late transcription) results from superimposed early and late transcriptional mechanisms acting on the same promoter.

1 August 2014 in Current Opinion in Virology
Verified
Journal Article
Closed access
MKMalika Kuzembayeva
Malika Kuzembayeva
MHMitchell Hayes
Mitchell Hayes
BSBill Sugden
Bill Sugden

22 January 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
WWWei Wang
Wei Wang
AUAayushi Uberoi
Aayushi Uberoi
Megan SpurgeonMegan Spurgeon
Megan Spurgeon
EGEllery Gronski
Ellery Gronski
VMVladimir Majerciak
Vladimir Majerciak
PLPaul Lambert
Paul Lambert
High-risk human papillomaviruses (HPVs) cause 5% of human cancers. Despite the availability of HPV vaccines, there remains a strong urgency to find ways to treat persistent HPV infections, as current HPV vaccines are not therapeutic for individuals already infected. We used a mouse papillomavirus infection model to characterize virus-host interactions. We found that mouse papillomavirus (MmuPV1) suppresses host immune responses via overexpression of stress keratins. In mice deficient for stress keratin K17 (K17KO), we observed rapid regression of papillomas dependent on T cells. Cellular genes involved in immune response were differentially expressed in the papillomas arising on the K17KO mice correlating with increased numbers of infiltrating CD8+ T cells and upregulation of IFNγ-related genes, including CXCL9 and CXCL10, prior to complete regression. Blocking the receptor for CXCL9/CXCL10 prevented early regression. Our data provide a novel mechanism by which papillomavirus-infected cells evade host immunity and defines new therapeutic targets for treating persistent papillomavirus infections. Persistent infection with high-risk human papillomavirus may lead to a variety of cancers in human including cervical cancer, anal cancer, head and neck cancer and skin cancer. There has been a lack of animal model to study how papillomavirus infection evades cellular immune surveillance to establish long-term infections to cause cancers. We utilized a mouse papillomavirus, MmuPV1, as an infection model in immunocompetent FVB/N mice to study how the virus escapes immune recognition to establish persistent infections. We found a novel regulator, stress keratin 17 (K17), was induced in expression following MmuPV1 infection, and that K17 was critical for preventing T cell infiltration in MmuPV1-induced papillomas by inhibiting the CXCL9/CXCL10/CXCR3 axis. Our study provides a new mechanism by which papillomaviruses evade T cell response following infection.